Martin Allen-Auerbach

University of California, Los Angeles — United States

Medicine · Health Sciences

36h-index5.0kcitations144works2.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(44), Radiomics and Machine Learning in Medical Imaging(28), Prostate Cancer Treatment and Research(27), Radiopharmaceutical Chemistry and Applications(25), CAR-T cell therapy research(24)

Publications144 total

Beyond the Prostate: Incidental Detection of Male Breast Carcinoma on [ 18 F]DCFPyl

Journal of Nuclear Medicine·2025Open Access

Figure S5 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

2025Open Access

Figure S6 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

2025Open Access

Table S2 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

2025Open Access

Figure S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

2025Open Access

Table S1 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

2025Open Access

Figure S4 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

2025Open Access

Figure S2 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

2025Open Access

Figure S3 from CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

2025Open Access

177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

3 cited

Journal of Clinical Oncology·2025· 3 citedOpen Access

177Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer: Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial

1 cited

International Journal of Radiation Oncology*Biology*Physics·2025· 1 cited

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny

1 cited

Nature Communications·2025· 1 citedOpen Access

Study protocol: Phase 2 trial of re-treatment with 177Lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA trial).

Journal of Clinical Oncology·2025

Studienprotokoll der laufenden FLEX-MRT Studie: Randomisierte Phase-2-Studie zur FLEXiblen und erweiterten Dosierung der [177Lu]Lu-PSMA-617 Molekularen RadioTherapie (FLEX-MRT) in Patienten mit mCRPC

Nuklearmedizin - NuclearMedicine·2025

Abstract 4145086: Determining the Prevalence of Genetic Cardiomyopathies in Non-Ischemic Cardiomyopathy Patients Undergoing Cardiac Positron Emission Tomography-Computed Tomography: A Single Institution Experience

Circulation·2024

Phase 2 Prospective Trial of Re-Treatment with177 lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer (RE-LuPSMA): Study Protocol

1 cited

International Journal of Radiation Oncology*Biology*Physics·2024· 1 citedOpen Access

Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data

9 cited

Journal of Nuclear Medicine·2024· 9 citedOpen Access

A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT).

1 cited

Journal of Clinical Oncology·2024· 1 cited

Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.

1 cited

Journal of Clinical Oncology·2024· 1 citedOpen Access

FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis

8 cited

European Journal of Nuclear Medicine and Molecular Imaging·2024· 8 cited

page 1 of 8Next →

Frequent Co-authors

Johannes Czernin(39), Matthias Benz(14), Ken Herrmann(14), Wolfgang Weber(12), Jérémie Calais(10), Wolfgang P. Fendler(9), Fritz C. Eilber(8), Michael E. Phelps(8), Pawan Gupta(8), Michael E. Phelps(7), Sarah Dry(6), William D. Tap(6), Matthias Eiber(6), Andrew Quon(6), Barbara J. Fueger(5), Magnus Dahlbom(5), Christiaan Schiepers(5), Wesley R. Armstrong(5), J Gartmann(4), Roger Slavik(4)